Plasbumin-5 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of hypovolemia and shock cases, expansion of critical care infrastructure, rising surgical procedure volumes, availability of plasma fractionation technologies, increased use of albumin in emergency care.

The growth in the forecast period can be attributed to increasing demand for advanced plasma-derived therapies, rising focus on patient blood management, expansion of icu capacity globally, growing adoption in liver and cardiac care, increasing investments in plasma collection infrastructure. Major trends in the forecast period include increasing use of plasma-derived volume expanders, rising demand for critical care albumin therapy, growing adoption in surgical and icu settings, expansion of high-purity albumin solutions, enhanced focus on hemodynamic stabilization.

The rising number of surgical procedures is expected to drive the growth of the Plasbumin-5 market. Surgical procedures are increasing due to advancements in medical technology, greater access to healthcare, and a growing demand for cosmetic and corrective treatments. Plasbumin-5 serves as a volume expander, helping to maintain blood volume, blood pressure, and tissue perfusion, particularly during surgery. It also plays a critical role in managing hypoproteinemia and supporting recovery and healing post-surgery. For example, in April 2025, the British Association of Aesthetic Plastic Surgeons, a UK-based surgical organization, reported that 27,462 cosmetic surgeries were performed in 2024, reflecting a 5% overall increase. As a result, the rising number of surgical procedures is driving the growth of the Plasbumin-5 market.

The rising incidence of burn injuries is also expected to drive the growth of the Plasbumin-5 market. Burn injuries, which result from heat, chemicals, electricity, radiation, or friction, cause damage to the skin or underlying tissues. Factors such as heat exposure, household accidents, and workplace hazards contribute to burn injuries. Plasbumin-5 helps restore blood volume, maintain circulatory pressure, and improve protein levels, supporting fluid balance and tissue repair in burn injuries. It prevents edema, reduces shock risk, and promotes faster recovery by maintaining osmotic pressure. For example, in August 2024, the American Burn Association reported 32,540 burn cases in 2023, compared to 30,135 in 2022, contributing to a total of 156,073 cases over five years. As a result, the rising incidence of burn injuries is driving the growth of the Plasbumin-5 market.

In December 2023, Grifols, a Spain-based provider of plasma-derived medicines, partnered with Haier Group through Shanghai RAAS (SRAAS) to expand the distribution of human serum albumin 5% (Plasbumin-5) in China. This collaboration aims to ensure a long-term albumin supply, extend exclusive distribution agreements, and meet the growing demand for plasma-derived therapies. The partnership highlights the focus of the Plasbumin-5 market on strengthening regional supply chains and ensuring consistent access to high-quality albumin products. Haier Group, through Shanghai RAAS (SRAAS), is a China-based provider of plasma and hemoderivative solutions.

Major companies operating in the plasbumin-5 market are Grifols Therapeutics LLC.

North America was the largest region in the plasbumin-5 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasbumin-5 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasbumin-5 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the plasbumin-5 market by increasing costs of imported plasma collection equipment, fractionation systems, sterile containers, and cold-chain storage materials. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported plasma processing technologies, while Asia-Pacific faces higher costs related to plasma sourcing and distribution. These tariffs raise treatment expenses and strain hospital procurement budgets. However, they are also encouraging domestic plasma fractionation investments, regional supply chain strengthening, and expanded local production of human albumin therapies.

The plasbumin-5 market research report is one of a series of new reports that provides plasbumin-5 market statistics, including plasbumin-5 industry global market size, regional shares, competitors with a plasbumin-5 market share, detailed plasbumin-5 market segments, market trends and opportunities, and any further data you may need to thrive in the plasbumin-5 industry. This plasbumin-5 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasbumin-5 is a sterile, human plasma-derived albumin solution designed to act as a volume expander for patients experiencing significant fluid loss. This highly purified therapy helps restore blood volume, stabilize blood pressure, and enhance the transport of vital substances throughout the body.

The primary formulations of Plasbumin-5 are liquid and lyophilized (powder). Liquid Plasbumin-5 is a ready-to-use intravenous albumin solution, formulated for rapid administration in emergency or clinical settings to quickly replenish albumin levels in patients. It is available in various packaging sizes, such as 50 milliliters (mL), 250 milliliters (mL), and 500 milliliters (mL). This formulation is used for several clinical indications, including hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass surgery, and acute liver failure. Plasbumin-5 is distributed through various channels, such as hospitals, clinics, and retail and specialty pharmacies, and is utilized by multiple end-users, including adult and geriatric patients.

The plasbumin-5 market consists of sales of human albumin intravenous solutions, sterile, and ready-to-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.